Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Licenses AAV Gene Delivery Technology from Stanford University

Published: Thursday, July 03, 2014
Last Updated: Thursday, July 03, 2014
Bookmark and Share
Agreement supplements existing exclusive rAAV gene targeting license from University of Washington.

Horizon Discovery™ Group announced it has entered into a non-exclusive license agreement with Stanford University to access intellectual property related to the use of a proprietary serotype of AAV (Adeno-Associated Virus) for commercial applications involving homologous recombination in gene editing. 

Created by Professor Mark Kay at Stanford this artificial serotype of AAV known as AAV-DJ effectively transduces (infects) a broader range of mammalian cells (>80%) than any naturally occurring AAV serotype, enabling Horizon to target an increased range of cell types. Combined with Horizon’s existing exclusive license for use of rAAV (recombinant Adeno-Associated Virus) from the University of Washington, the Company is the sole source of this effective and highly precise mechanism for gene editing.

“Horizon is committed to ensuring our customers are supported by the widest range of gene editing tools secured by appropriate licenses, enabling us to offer the most complete suite of gene editing products and services to meet their needs,” commented Eric Rhodes, CTO, Horizon.

In February 2014 Horizon announced the launch of its GENASSIST™ range of gene editing kits and reagents that enable easier, robust implementation of CRISPR and rAAV gene editing experiments. The current GENASSIST offering comprises both off-the-shelf reagents for using CRISPR editing technology and a unique kit combination of these reagents to allow customers to generate their own CRISPR-ready cell lines that constitutively express Cas9-nickase.

Horizon offers researchers an unrivalled toolbox capable of performing rapid functional genomics experiments, and creating high-precision human disease models for deployment at all stages of drug discovery and diagnostic development.  Horizon employs three genome editing technologies (AAV, ZFN and CRISPR) for custom client-led projects, and is continually expanding upon its own menu of over 550 genetically-defined off-the-shelf disease model cell lines and related products. 

Horizon continues to review the gene editing field for further product expansion and IP licensing opportunities.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Discovery Announces Two Fresh Licensing Agreements
Horizon Discovery licenses biomanufacturing cell lines to Centre for Process Innovation (CPI) and National Institute for Bioprocessing Research and Training (NIBRT).
Tuesday, September 13, 2016
Horizon, Fulcrum Launch Collaboration
Horizon Discovery and Fulcrum Therapeutics form collaboration for novel CRISPR-based target discovery in genetic diseases.
Tuesday, September 06, 2016
Horizon, Ventana Sign Co-Development Agreement
The agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standards.
Friday, September 02, 2016
Wistar, Horizon Ink Exclusive License Deal
The Wistar Institute has granted Horizon Discovery an exclusive license to 153 of its Melanoma Patient-Derived Xenograft models.
Thursday, July 21, 2016
Horizon, Centauri Therapeutics Launch Collaboration
Joint venture creates a differentiated new player in the rapidly growing immuno-oncology market, currently valued at £25 billion.
Thursday, March 03, 2016
Horizon Signs Three Diagnostic Agreements Worth an Initial $3.3 Million
Agreements with three global companies for test development and validation.
Thursday, November 26, 2015
Horizon Launches New E-commerce Platform and Expands UK Headquarters
Key investment includes an integrated web-shop and Enterprise Resource Planning system to support further scale and revenue growth.
Thursday, October 29, 2015
Horizon, Swift Partner on Genomic Reference Standards
Standards to be used to support validation, consistency and accuracy of the panel.
Wednesday, October 28, 2015
Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Enters Licensing Agreement with LakePharma
The terms of the license cover commercial use of a genetically-engineered Chinese Hamster Ovary (CHO) cell line, developed by Horizon and adapted to manufacturing conditions by LakePharma.
Thursday, September 17, 2015
Horizon Enters Bioproduction Cell Line Licensing Agreement with LakePharma, Inc.
LakePharma to take a full commercial license for GS null CHO K1 cell line from Horizon for improved efficiency in biopharmaceutical manufacturing.
Wednesday, September 16, 2015
Horizon, Abcam Sign License and Supply Agreement
Horizon Discovery Group plc and Abcam plc have announced the formation of a license and supply agreement between the two companies.
Wednesday, September 09, 2015
Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
CareDx and Horizon Enter into a Collaboration
Horizon’s standards to support proficiency testing of CareDx solid organ transplantation injury monitoring diagnostic assay.
Thursday, June 04, 2015
Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
Grahame brings over 20 years’ experience to Horizon.
Thursday, May 14, 2015
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!